Drug Trial Radar · NCT06940830
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
252
Actual
Start
May 21, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- PSI CRO
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
Conditions
- Hemophilia A
Interventions
Efanesoctocog alfaDrug
Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized joint bleeding rate (AjBR) over the prospective observation period.Time frame: Enrolment to Month 12, 24 and 36
Locations
31 sites in 8 countries. Site status is shown where the registry gives one.
Sobi Investigational Site
Zagreb, Croatia
Sobi Investigational Site
Brno, Czechia
Sobi Investigational Site
Ostrava, Czechia
Sobi Investigational Site
Prague, Czechia
Sobi Investigational Site
Bordeaux, France
Sobi Investigational Site
Marseille, France
Sobi Investigational Site
Montpellier, France
Sobi Investigational Site
Nantes, France
Sobi Investigational Site
Paris, France
Sobi Investigational Site
Rennes, France
Sobi Investigational Site
Rouen, France
Sobi Investigational Site
Berlin, Germany
Sobi Investigational Site
Bonn, Germany
Sobi Investigational Site
Frankfurt am Main, Germany
Sobi Investigational Site
Hamburg, Germany
Sobi Investigational Site
Munich, Germany
Sobi Investigational Site
Dublin, Ireland
Sobi Investigational Site
Catania, Italy
Sobi Investigational Site
Padua, Italy
Sobi Investigational Site
Salerno, Italy
Sobi Investigational Site
Turin, Italy
Sobi Investigational Site
A Coruña, Spain
Sobi Investigational Site
Barcelona, Spain
Sobi Investigational Site
Málaga, Spain
Sobi Investigational Site
Palma de Mallorca, Spain
Sobi Investigational Site
Zaragoza, Spain
Sobi Investigational Site
Salamanca, Castille and León, Spain
Sobi Investigational Site
Birmingham, United Kingdom
Sobi Investigational Site
Cardiff, United Kingdom
Sobi Investigational Site
London, United Kingdom
Sobi Investigational Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.